Enovis Co. (NYSE:ENOV) Receives Average Recommendation of “Moderate Buy” from Brokerages

Shares of Enovis Co. (NYSE:ENOV) have earned a consensus rating of “Moderate Buy” from the seven ratings firms that are currently covering the firm, Marketbeat Ratings reports. One analyst has rated the stock with a hold rating and six have given a buy rating to the company. The average 1 year target price among brokers that have issued ratings on the stock in the last year is $65.86.

Separately, Needham & Company LLC reaffirmed a “buy” rating and issued a $65.00 price objective on shares of Enovis in a research note on Thursday, November 7th.

Institutional Trading of Enovis

A number of hedge funds have recently bought and sold shares of ENOV. UMB Bank n.a. raised its holdings in shares of Enovis by 128.2% during the fourth quarter. UMB Bank n.a. now owns 778 shares of the company’s stock valued at $34,000 after acquiring an additional 437 shares during the period. Pinnacle Bancorp Inc. raised its stake in Enovis by 54.5% during the 4th quarter. Pinnacle Bancorp Inc. now owns 850 shares of the company’s stock valued at $37,000 after purchasing an additional 300 shares during the period. DekaBank Deutsche Girozentrale acquired a new stake in Enovis during the 3rd quarter valued at $55,000. FMR LLC lifted its holdings in shares of Enovis by 20.5% in the third quarter. FMR LLC now owns 2,840 shares of the company’s stock valued at $122,000 after purchasing an additional 484 shares in the last quarter. Finally, Heritage Family Offices LLP acquired a new stake in shares of Enovis in the third quarter worth $206,000. 98.45% of the stock is owned by hedge funds and other institutional investors.

Enovis Trading Down 1.5 %

Shares of ENOV stock opened at $44.09 on Monday. The company has a quick ratio of 1.12, a current ratio of 2.27 and a debt-to-equity ratio of 0.40. The stock has a 50-day simple moving average of $45.82 and a 200 day simple moving average of $44.48. Enovis has a fifty-two week low of $38.27 and a fifty-two week high of $65.03. The stock has a market capitalization of $2.51 billion, a P/E ratio of -20.13 and a beta of 1.94.

About Enovis

Enovis Corporation operates as a medical technology company focus on developing clinically differentiated solutions worldwide. It also manufactures and distributes medical devices which are used for reconstructive surgery, rehabilitation, pain management, and physical therapy. The company operates through Prevention and Recovery, and Reconstructive segments.